Food and Drug Administration (FDA) Advisory Panel to Vote on Grail’s Galleri Multi-Cancer Blood Test

The FDA’s Molecular and Clinical Genetics Panel will meet on September 23 2026 to consider Grail Inc.’s pre-market approval (PMA) for Galleri, a blood test that screens adults 50+ for multiple cancers. The panel will vote on safety, effectiveness, and risk-benefit balance before the agency decides.

RTTNews

Galleri is a prescription-only, next-generation-sequencing (NGS) in-vitro diagnostic that detects cancer-specific methylation patterns in cell-free DNA from a blood draw. It reports “Cancer Signal Detected” or “No Cancer Signal Detected” and, when positive, suggests one of 18 tissue origins. Grail has offered Galleri under CLIA regulations since 2021 but has never received FDA marketing authorization. The company received Breakthrough Device Designation in 2018, and the PMA filing was submitted on January 29 2026.

GRAIL Shares Surged As FDA Staff Reviews Galleri Multi-Cancer Blood Test Grail stock surges as FDA finds no major concerns with cancer test FDA Panel Review of GRAIL’s Galleri Multi-Cancer Early Detection Test Grail Shares Surge 34% as FDA Review of Cancer Early Detection Test Shows No Major Concerns — BigGo Finance Grail Shares Climb as FDA Staff Find No Major Safety or Accuracy Concerns for Galleri Cancer Test — BigGo Finance Grail stock surges 36% on positive FDA briefing docs for Galleri test NPR

• PATHFINDER 2 (U.S.): 35 % 12-month sensitivity, 99.85 % specificity, 0.49 % cancer detection rate (?202 screens per cancer).

GRAIL Shares Surged As FDA Staff Reviews Galleri Multi-Cancer Blood Test

• NHS-Galleri (U.K.): 31.6 % sensitivity, 99.74 % specificity, 0.51 % detection rate (?196 screens per cancer).

GRAIL Shares Surged As FDA Staff Reviews Galleri Multi-Cancer Blood Test

• Stage-specific sensitivity (combined): 13.6 % (stage I) to 60.0 % (stage IV).

NPR

• Safety: 72.9 % of positive cases underwent at least one invasive follow-up; adverse events occurred in 4.1 % of those, none serious or device-related.

GRAIL Shares Surged As FDA Staff Reviews Galleri Multi-Cancer Blood Test

• Cost: approximately $949 per draw.

Grail stock surges 36% on positive FDA briefing docs for Galleri test

• Market reaction: Grail’s shares rose 35 % after FDA staff released briefing documents indicating no major safety or analytical concerns.

Reuters

• FDA staff reported no outstanding questions on analytical performance or safety but asked advisers to consider whether the data support labeling Galleri as an “early detection” test.

Reuters

• Grail says the test complements, not replaces, existing screenings such as mammograms and colonoscopies.

Reuters

• The U.K. NHS-Galleri trial (140,000+ participants) did not meet its primary endpoint of a statistically significant reduction in late-stage cancers.

NPR

• The U.S. PATHFINDER 2 study was not designed to show mortality reduction, leaving uncertainty about whether annual testing lowers cancer deaths.

NPR

• Long-term outcome data are lacking to confirm whether repeated testing shifts diagnoses to earlier stages across cancer types.

NPR

• “It's a new era for early cancer detection, and if the FDA approves it, it validates the overall concept,” — Cristian Tomasetti, City of Hope

NPR

• “We view this as constructive for Grail,” — Piper Sandler

Reuters

The advisory panel’s vote on September 23 2026 will guide the FDA’s final decision, expected in the first half of 2027. Approval would make Galleri the first FDA-authorized multi-cancer early-detection test and could expand Medicare and private-insurer coverage for the $949 assay.

NPR